Search

Your search keyword '"Wondergem, Mariëlle"' showing total 13 results
Start Over Author "Wondergem, Mariëlle" Journal blood
13 results on '"Wondergem, Mariëlle"'

1. Impact of etoposide and ASCT on survival among patients aged

Author

Brink, Mirian, Meeuwes, Frederik O., van der Poel, Marjolein W.M., Kersten, Marie José, Wondergem, Mariëlle, Mutsaers, Pim G.N.J., Böhmer, Lara H., Woei-A-Jin, F. J. Sherida H., Visser, Otto, Oostvogels, Rimke, Jansen, Patty M., Plattel, Wouter, Huls, Gerwin A., Vermaat, Joost S.P., and Nijland, Marcel

Published
2022
Full Text
View/download PDF

3. Siremadlin, a Human Double Minute-2 (HDM2) Inhibitor, Added to Ruxolitinib after Suboptimal Response to Ruxolitinib Alone in Patients with Myelofibrosis: Results from Part 1 of the Phase 1/2 Adore Study

Author

Heidel, Florian H, Perkins, Andrew Charles, Reiter, Andreas, Crodel, Carl C., Riley, Caroline Hasselbalch, Gómez-Casares, María Teresa, Takacs, Istvan, Becker, Heiko, Lehmann, Thomas, Vinogradova, Olga, Burbury, Kate, Vannucchi, Alessandro M., Gupta, Vikas, Harrison, Claire, Wondergem, Marielle, Kiladjian, Jean-Jacques, Cleary, Grace, Zhang, Angela, Mahuzier, Bruyère, Kota, Jagannath, Prahallad, Anirudh, and Ross, David M

Published
2022
Full Text
View/download PDF

4. First-Line Treatment and Survival of Stage I(E) Peripheral T-Cell Lymphoma in the Netherlands; A Nationwide Population-Based Cohort Study

Author

Meeuwes, Frederik O., primary, Brink, Mirian, additional, Van Der Poel, Marjolein W.M., additional, Kersten, Marie José, additional, Wondergem, Mariëlle, additional, Mutsaers, Pim G.N.J., additional, Böhmer, Lara H., additional, Woei-a-Jin, F.J. Sherida H., additional, Visser, Otto J., additional, Oostvogels, Rimke, additional, Jansen, Patty M., additional, Neelis, Karen J., additional, Crijns, Anne P.G., additional, Daniëls, Laurien A., additional, Vermaat, Joost S.P., additional, Huls, Gerwin A., additional, and Nijland, Marcel, additional

Published
2021
Full Text
View/download PDF

5. Modulation of TGF-β Superfamily Signaling By Ker-050 Demonstrated Potential to Treat Myelofibrosis and Mitigate Ruxolitinib-Associated Cytopenia

Author

Harrison, Claire N, Ross, David M., Chee, Lynette C.Y., Tan, Shuhying, Wondergem, Marielle, Devos, Timothy, Graham, Christine, McGinty, Allie, Pace, Michael, Wang, Hongying, Jiang, Ying, Bobba, Suresh, Dawson, Katie Louise, Rovaldi, Christopher, Hankin, Montagu, Grayson, Dena, Cooper, Simon, and Salstrom, Jen L.

Published
2023
Full Text
View/download PDF

8. IMPACT OF ETOPOSIDE AND ASCT ON SURVIVAL AMONG PATIENTS <65 YEARS WITH STAGE II-IV PTCL; A POPULATION-BASED COHORT STUDY

Author

Brink, Mirian, Meeuwes, Frederik O., van der Poel, Marjolein W.M., Kersten, Marie-José, Wondergem, Mariëlle, Mutsaers, Pim G.N.J., Böhmer, Lara, Woei-A-Jin, F.J. Sherida H., Visser, Otto, Oostvogels, Rimke, Jansen, Patty M., Plattel, Wouter, Huls, Gerwin A., Vermaat, Joost S.P., and Nijland, Marcel

Abstract

Patients <65 years with peripheral T-cell lymphoma are treated with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP). While the addition of etoposide and consolidation with autologous stem cell transplantation (ASCT) are preferred in some countries, randomized trials are lacking. This nationwide population-based study assessed the impact of etoposide and ASCT on overall survival (OS) among patients aged 18-64 years with stage II-IV anaplastic large T-cell lymphoma (ALCL), angioimmunoblastic T-cell lymphoma (AITL) and peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), diagnosed between 1989-2018, utilizing the Netherlands Cancer Registry. Patients were categorized into two calendar periods, which represent the pre- and post-era of etoposide and ASCT implementation, respectively. A total of 1,427 patients were identified (35% ALCL, 21% AITL and 44% PTCL-NOS). OS increased from 39% in 1989-2009 to 49% in 2009-2018 (p<0·01). The 5-year OS was superior for patients treated with CHOEP, as compared to patients with CHOP (64% and 44%, respectively; p<0·01). When adjusted for subtype, IPI-score, and ASCT, the risk of mortality was similar between the two groups, except for ALK+ ALCL patients for whom risk of mortality was 6.3 times higher when treated with CHOP as compared to CHOEP. Patients consolidated with ASCT demonstrated a superior 5-year OS of 81% as compared to 39% for patients not receiving an ASCT (p<0·01), regardless of whether a complete remission was achieved. In patients <65 years with advanced stage ALK- ALCL, AITL and PTCL, the use of ASCT consolidation, but not the addition of etoposide, was associated with improved OS.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results